← All indications
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Subtype terms (9)
More specific conditions that are subtypes of Inflammation in the MeSH hierarchy.
- Acute-Phase Reaction
5 drugs (1 approved, 4 experimental)
- Foreign-Body Reaction
1 drug approved
- Neurogenic Inflammation
4 drugs (1 approved, 3 experimental)
- Neuroinflammatory Diseases
13 drugs (6 approved, 7 experimental)
- Seroma
8 drugs (7 approved, 1 experimental)
- Serositis
- Suppuration
- Systemic Inflammatory Response Syndrome
54 drugs (34 approved, 20 experimental)
- Thromboinflammation
Drugs by status
Approved for this indication (64)
- magnesium isoglycyrrhizinate
- ophiochepalus striatus extract
- bromfenac
- palmitic acid
- ginseng
- lamivudine
- gentamicin
- cocoa bean
- glycyrrhizin
- polymyxin b sulfate
- aronia extract
- ketorolac
- rimexolone
- loteprednol
- lidocaine
- methylprednisolone
- carboxymethyl glucan
- formocortal
- coptis chinesis
- prednisone
- sulfacetamide
- tobramycin
- nepafenac
- kushen
- cyclosporine
- acetic acid
- serratiopeptidase
- parametaxylenol
- oxymatrine
- iguratimod
- +34 more
Phase 4 trials (131)
- dexlansoprazole
- triamcinolone
- soybean oil
- lovastatin
- etonogestrel
- secukinumab
- azelaic acid
- celecoxib
- vildagliptin
- etanercept
- policosanol
- lifitegrast
- oxymetazoline
- cellulose
- adalimumab
- collagen
- metronidazole
- pioglitazone
- sufentanil
- ticagrelor
- iodoform
- tildrakizumab
- sodium acetate
- liraglutide
- ramipril
- mycophenolate
- alemtuzumab
- formoterol
- rocuronium
- maraviroc
- +101 more
Phase 3 trials (74)
- tetryzoline
- oritavancin
- clarithromycin
- dupilumab
- oxygen
- viusid
- midazolam
- fluticasone
- ziltivekimab
- vancomycin
- minocycline
- bevacizumab
- fentanyl
- acarbose
- igm enriched immunoglobulins
- allopurinol
- soybean
- tea
- ammonium lactate
- infliximab
- Vinpocetine
- naproxen
- acetylsalicylic acid
- bovine intestinal alkaline phosphatase
- brazilian green propolis extract
- vitis vinifera
- ubiquinol
- salsalate
- mapracorat
- nimesulide
- +44 more
Phase 2 trials (105)
- autologous adipose-derived mesenchymal stem cells
- sugammadex
- rev131
- whey protein
- tirzepatide
- sodium nitrate
- niacin
- fluvastatin
- vvn461
- epoetin
- oxytocin
- l-epigallocatechin
- arginine
- clazakizumab
- papaya
- larazotide acetate
- mas825
- xt-150
- rifaximin
- tofacitinib
- rx-10045
- ritonavir
- melphalan
- creatine
- orticumab
- wheat
- mesalamine
- live attenuated varicella vaccine
- fab-fragment of anti-human cd4
- decidual stromal cells
- +75 more
Phase 1 trials (78)
- lexaptepid pegol
- glucose
- bnt162b2
- lanraplenib
- aldosterone
- piperine
- methionine
- efavaleukin alfa
- abatacept
- rivaroxaban
- atazanavir
- wobenzyme
- adenosine
- meropenem
- gimsilumab
- mmi-0100
- azd673
- ashwagandha extract
- mt1980
- cep-37440
- pyridoxamine
- glucagon-like peptide-1
- mrna-1273
- typhoid vi polysaccharide vaccine
- nitroprusside
- zinc gluconate
- acetylcholine chloride
- leo 158968
- nnc0215-0384
- mmv367
- +48 more
Other trials (211)
- desloratadine
- glycine
- jing-si
- brazil nut
- zinc
- 3-hydroxybutyrate
- sargramostim
- pomegranate
- metamizole
- morphine
- ginger
- sevelamer
- glecaprevir
- kang fu
- hydrogen
- cefixime
- ozone
- betula
- mulberry leaf extract
- bifidobacterium rhamnosus
- flavonoids
- aloe vera
- broccoli sprout extract
- cloudberry
- elemental gold
- flavanol
- ropivacaine
- ergothioneine
- isotretinoin
- black pepper
- +181 more
Organizations
Organization Involved with Phase 4 Indications (218)
- University of Illinois at Chicago
- University of New South Wales
- United Arab Emirates University
- Seoul National University
- Instituto di Biomedicina ed immunologia molecolare
- Shahid Beheshti University of Medical Sciences
- Radboud University
- National Institute of Mental Health (NIMH)
- American College of Clinical Pharmacy
- Noordwest Ziekenhuisgroep
- University Clermont Auvergne
- University of Padova
- Fundacio Lluita Contra la SIDA
- Yuhan Pharmaceutical Company
- Rio de Janeiro State University
- University of Sharjah
- Hospital General Universitario Gregorio Marañon
- Government of Taiwan
- University of Western Australia
- University of Alabama, Birmingham
- Fundación Renal Iñigo Alvarez De Toledo
- University of Pennsylvania
- Pierre Fabre
- Leo Pharma
- University of Brasilia
- Hospital Son Llatzer
- New England Retina Associates
- University of Amsterdam
- Takeda
- Innovaderm
- +188 more
Organization Involved with Phase 3 Indications (168)
- George Washington University
- Iran University of Medical Sciences
- National Institute on Aging (NIA)
- Thomas Jefferson University
- Medical College of Wisconsin
- University of Namibia
- University of Limerick
- KLE Society's Institute of Dental Sciences
- D'Annunzio University of Chieti–Pescara
- Octapharma
- University of Nice Sophia Antipolis
- Fondation Apicil
- Health Research Board, Ireland
- Singapore General Hospital
- Ache Laboratorios Farmaceuticos S.A.
- Actavis
- Sponsor GmbH
- Sall Research Medical Center
- Department of Defense
- Bambino Gesù Hospital and Research Institute
- University of Edinburgh
- Universidade Federal de Minas Gerais
- Federal University of Minas Gerais
- University of Sao Paulo
- Los Angeles Biomedical Research Institute
- University of Erlangen-Nuremberg
- Pennsylvania State University
- RWTH Aachen University
- Raymond Fong, MDPC
- SPARC
- +138 more
Organization Involved with Phase 2 Indications (194)
- Capital Medical University
- Shenzhen maternal and child health care hospital
- Integra LifeSciences Corporation
- Eyegate Pharmaceuticals, Inc.
- Ragon Institute of MGH, MIT and Harvard
- Virginia Commonwealth University
- Drexel University
- Athera Biotechnologies AB
- Biosearch S.A.
- Texas Heart Institute
- Northern Ireland Clinical Trials Unit
- LycoRed Ltd.
- University of Monastir
- Atopix Therapeutics, Ltd.
- National Cancer Institute (NCI)
- Genentech
- ChromaDex
- AIDS Healthcare Foundation
- National Eye Institute (NEI)
- University of Grenoble
- Jiao Tong University
- Vita-Salute University of Milano. Italy
- Medaimun GmbH
- Fujian Medical University
- Evolutec Group
- VIA Pharmaceuticals
- Foresee Pharmaceuticals Co., Ltd.
- Hospital Sao Rafael
- Southampton University Hospital NHS Foundation Trust
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- +164 more
Organization Involved with Phase 1 Indications (42)
- CPR Pharma Services Pty Ltd, Australia
- Technical University of Munich
- Probi AB
- Pulmatrix Inc.
- Synspira, Inc.
- Institute for Neurodegenerative Disorders
- Covance
- Polymun Scientific GmbH
- PRACS
- Innate Pharma
- Doris Duke Charitable Foundation
- University of Hawaii
- Clinical Network Services
- Noxxon AG
- Bayer
- St. Louis University
- Universitaire du Sart-Tilman
- Red River Clinical
- National College of Natural Medicine
- University of Texas, Galveston
- Lund University
- Celtaxsys, Inc.
- Stiefel Laboratories
- Dasman Diabetes Institute
- Sandoz
- National Institute of General Medical Sciences (NIGMS)
- Tibotec
- Moerae Matrix, Inc.
- Rutgers University
- Kinevant Sciences GmbH
- +12 more
Organization Involved with Other Experimental Indications (182)
- University of Southern Denmark
- Marywood University
- Agriculture and Agri-Food Canada
- Nestle
- Bend Beauty Inc.
- Fudan University
- Scott and White Healthcare
- Prevention Pharmaceuticals
- Northwell Health
- Fairfield University
- Manzo Pharmaceuticals
- Nicolaus Copernicus University
- Nordic Centre of Excellence
- Universidad Católica San Antonio de Murcia
- Illinois Institute of Technology
- K. Halstensen AS
- Aalborg University
- Northumbria University
- University of Guelph
- University of Mary Hardin-Baylor
- Tandlaegeforeningen, Calcin fonden
- Clasado Biosciences
- Atrium Innovations
- Meir Medical Center
- University of Heidelberg
- University of Ulm
- The John van Geest Cancer Research Centre
- Arla Foods
- The Gerber Foundation
- Thrasher Research Fund
- +152 more